BEAT

Rating neutralAI MemoPost-earnings T+1

HeartBeam

As of 2026-08-07/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results call remains upcoming • 2026-08-13

Expected move: +18%

Biggest risk

No confirmed Q2 results, consensus comparison, guidance revision, analyst target change, or post-print market attribution is available. Commercialization remains early, while Nasdaq compliance and financing risk remain material.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

At roughly $0.51, successful licensing or commercialization commentary and credible ALIGN-ACS/FDA progress could create substantial upside. The scheduled call is the next decision point [#PR-EARNINGS-2026-07-30].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-07

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Nasdaq minimum-bid compliance overhang
ALIGN-ACS pilot data and FDA-path clarification
At roughly $0.51, successful licensing or commercialization commentary and credible ALIGN-ACS/FDA progress could create substantial upside.

BearKey bullets

Commercial adoption, licensing economics, and the FDA path for heart-attack detection remain unproven.
Low coverage and unavailable analyst revisions limit confidence in valuation and market-reaction interpretation.
Nasdaq minimum-bid compliance risk remains material through December 28, 2026 [#SEC-8K-2026-07-02].

WatchKey bullets

Q2 2026 results call remains upcoming

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $1 (p=55%)

Bull/Bear spread: +86% / -47%

Vs latest close: Bull +86% · Base +18% · Bear -47%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $1 (p=55%)Bear Target: $0 (p=25%)

Commentary

Issuer news flow is constructive around pilot enrollment and the planned strategy update, but the apparent earnings follow-up has not produced a confirmed Q2 release. The company’s investor-relations calendar still points to August 13, and analyst revisions, options data, short interest, and social coverage are unavailable or insufficient. Treat this as a cautious monitoring view rather than a post-earnings confirmation [#PR-EARNINGS-2026-07-30].

As of 2026-08-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Nasdaq minimum-bid compliance overhang
ALIGN-ACS pilot data and FDA-path clarification

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$1 / p=55% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Price $1 as of 2026-08-06

Nearest Scenario: Base (∆ 18%)

Targets vs latest close: Bull +86% · Base +18% · Bear -47%

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-13
Q2 2026 results call remains upcoming
The scheduled follow-up does not yet have a confirmed earnings print: HeartBeam’s company release says Q2 results will be discussed on August 13, with a release beforehand [#PR-EARNINGS-2026-07-30]. No Q2 surprise, guidance change, or analyst reaction is currently available.
Prob 95.00% • Move 18.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Nasdaq minimum-bid compliance overhang
2026-12-28
The prior baseline identifies a Nasdaq deficiency notice and a December 28, 2026 deadline to regain compliance; failure could lead to delisting proceedings [#SEC-8K-2026-07-02].
Prob 65% • Move -18% • Priced-in 70%

Long-term Catalysts

Months to a year

ALIGN-ACS pilot data and FDA-path clarification
2026-10-16
Enrollment was completed ahead of schedule, with data intended to inform a potential U.S. pivotal study and expanded FDA indication [#IR-2026-06-30]. Execution and commercialization remain unproven.
Prob 55% • Move 35% • Priced-in 30%

Risks

Commercial adoption, licensing economics, and the FDA path for heart-attack detection remain unproven.
Low coverage and unavailable analyst revisions limit confidence in valuation and market-reaction interpretation.
Nasdaq minimum-bid compliance risk remains material through December 28, 2026 [#SEC-8K-2026-07-02].
The scheduled post-earnings trigger appears premature because the company still lists the Q2 call for August 13; no earnings surprise or guidance data is confirmed.

Peers

Symbol	Summary
ARAY	Small-cap medical-device execution comparator, but product and procedure dynamics are not directly comparable.
NSPR	Small-cap medtech comparator with relevant commercialization and financing considerations, but a different device category.
ABT	Strategic-scale cardiac benchmark; useful for framing HeartBeam’s missing validation, distribution, reimbursement, and financial depth.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-07

Loading AI feed…

Symbol

Summary

ARAY

Small-cap medical-device execution comparator, but product and procedure dynamics are not directly comparable.

NSPR

Small-cap medtech comparator with relevant commercialization and financing considerations, but a different device category.

ABT

Strategic-scale cardiac benchmark; useful for framing HeartBeam’s missing validation, distribution, reimbursement, and financial depth.